Decapeptyl Depot
Decapeptyl Depot 3.75 mg
Qty:TotalItem priceSaving
1 syringe $262.00 $262.00 -
Decapeptyl Depot (Triptorelin) is a gonadotropin-releasing hormone agonist (GnRH agonist). By causing constant stimulation of the pituitary, Decapeptyl Depot decreases pituitary secretion of gonadotropins luteinizing hormone (LH) and follicle stimulating hormone (FSH). Like other GnRH agonists, Decapeptyl Depot may be used in the treatment of hormone-responsive cancers such as prostate cancer or breast cancer, precocious puberty, estrogen-dependent conditions (such as endometriosis or uterine fibroids), and in assisted reproduction.
 
Decapeptyl Depot is indicated in the man in advanced prostate cancer-the treatment of attack, before using the extended release form. The effect of Decapeptyl Depot is much more favorable in patients who received other hormonal treatment. Women while in treatment of female infertility. This treatment is associated with other hormonal therapies (gonadotrophin) for in vitro fertilization followed by embryo transfer. Decapeptyl Depot is a type of hormonal therapy used to treat advanced prostate cancer.
 
Prostate Cancer: Most prostate cancers need a supply of the hormone testosterone to grow. Testosterone is produced by the testes and the adrenal glands. Production of testosterone by the testes is stimulated by another hormone called luteinising hormone. This is produced by the pituitary gland, which is situated in the brain. Triptorelin reduces the production of luteinising hormone, which leads to a reduction in testosterone levels. This may shrink or slow down the development of the cancer.
 
The man taking a daily dose of Decapeptyl Depot (Triptorelin) can increase blood levels of initial LH and FSH that causes increased blood levels of testosterone page. Continued therapy reduces the levels of LH, FSH levels that decrease testosterone administration throughout the product. In parallel we can see an increase in initial onset transient acid phosphatase treatment. During treatment there is a noticeable improvement in functional and objective data. Early treatment can be seen increased clinical symptoms (especially bone pain), but these events are rare and generally transient. They cause surveillance in the first two weeks of treatment, especially in patients at risk of obstruction of the excretory or spinal nerve compression (vertebral metastases). Testosterone should be checked periodically and should not exceed 1 mg / ml. Response is evaluated by bone scintigraphy examination and the prostate (except clinical examination and digital rectal examination) by ultrasound or CT.
 
The female fertility: ovarian response to gonadotrophin Decapeptyl Depot (Triptorelin) association at the same dose may vary from one patient to another and in some cases from one cycle to another for the same patient. More attention should be given to patients with polycystic ovaries. Ovarian induction should not be done only under medical supervision and regular clinical and biological controls: plasma estrogen dose, ultrasound. Other possible effects of the medicine: that all active drugs, this drug can, in some people, effects more or less embarrassing.
 
Most common side effects: hypersensitivity reactions, headache, tiredness and sleep disturbances.
 
Most common side effects at men: hot flushes, impotence, loss of libido, rarely gynecomastia and testicular atrophy. Most common side effects at women: hot flushes, bleeding or spotting, vaginal dryness or dyspareunia, reversible trabecular bone loss.
 
Decapeptyl Depot is available in 0.1mg and 3.75mg strength versions. When given to prevent premature luteinizing hormone surges in female patients, the dosage is 0.1mg per day. However, the dosage for treatment of prostate cancer in men or endometrioses in women is 3.75mg given every 28 days. Individual factors will need to be considered in more detail before the exact dosage can be calculated.
In order to add review, please log in

No review yet

To ask or answer questions, please register or log in an account.

No questions yet